Trials / Completed
CompletedNCT04736810
A Study of Penpulimab Combination Therapy in Patients With Advanced Nasopharyngeal Carcinoma
A Phase II Study of Penpulimab Combined With Chemotherapy ± Anlotinib Hydrochloride in Patients With Advanced Nasopharyngeal Carcinoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- Akeso · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-center, randomized, open-label, phase II study to evaluate the efficacy and safety of anti-PD-1 antibody Penpulimab (AK105) combined with chemotherapy ± anlotinib hydrochloride in the first-line treatment of patients with advanced nasopharyngeal carcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | AK105 | IV infusion |
| DRUG | Cisplatin | IV infusion |
| DRUG | Gemcitabine | IV infusion |
| DRUG | Anlotinib hydrochloride | Oral administration |
Timeline
- Start date
- 2021-02-25
- Primary completion
- 2022-06-09
- Completion
- 2023-12-18
- First posted
- 2021-02-03
- Last updated
- 2025-03-07
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04736810. Inclusion in this directory is not an endorsement.